Written by and the CAM-Cancer Consortium.
Updated January 1, 1970

Does it work?

No controlled clinical studies have investigated the effects of colostrum use in cancer patients and three case series are available.

Case series/studies

The earliest identifiable study, a case series, was conducted by Lewison and colleagues (1960).15 Seventeen women with advanced breast cancer received 1.1 litre of bovine colostrum per day for periods between 5 and 595 days. All patients were in a palliative or preterminal treatment situation without further options of conventional cancer therapy. Eleven of them received colostrum from cows that were injected with a homogenate of human breast cancer tissue in the udder. At the end of the observation period, two patients were alive and 15 had died. In no patient a remission of the cancer disease was seen. Ten patients reported periods of subjective improvement. Study authors evaluated their attempt of “passive immunization therapy” with bovine colostrum as “unsuccessful”.

Inoue and colleagues (1998) reported on a case series with 9 patients suffering from severe graft-versus-host-disease (GvHD) after bone marrow transplantation.3 Patients received 20 ml of human colostrum for 5 consecutive days. Clinical stage of GvHD improved in 6 patients.

Another case series investigated the use of a bovine immunoglobulin product (IgG) that was concentrated from the colostrum of cows immunized with killed Candida albicans germs.16 Out of 59 bone marrow transplant recipients, 19 received orally 10 g of the colostrum concentrate as dissolved powder containing 4.2 g of IgG. The product was given from day 4 before bone marrow transplantation to day 28 after transplantation. Ten of the IgG-treated patients showed a high level of Candida colonization as evaluated in mouth wash prior to colostrum administration. In 7 of these 10 patients, a reduction in colonization burden was seen during colostrum treatment.

The results of all three case series cannot be generalised to other patients or settings and it remains open whether the observed improvements in subjective and clinical status or the reduction of Candida colonization can be attributed to the colostrum intake. Furthermore, the latter study did not evaluate the intended clinical effect of this putative prophylactic measure against invasive candida infections, i.e. the reduction of these infections. According to current guidelines for the treatment of bone marrow transplant patients, antimycotic prophylaxis does not lead to a reduction of mortality in transplant recipients.17 Therefore the clinical relevance of the findings of the Candida study seems at present questionable.


, CAM-Cancer Consortium. [online document]. http://www.cam-cancer.org. January 1, 1970.

Document history